AbbVie, Allergan, Ugh

DEREK LOWE | June 26, 2019

article image
News broke yesterday morning (first at the Wall Street Journal, I believe) that Abbvie has agreed to acquire Allergan. This is one of the larger pharma mergers of recent years, and regular readers of this site will have a pretty good idea of the sigh and roll of the eyes with which I greet it. I think Ed Silverman at Stat‘s Pharmalot does a good job capturing the mood.

Spotlight

Pharma D&S

Pharma D&S was born in 2001 as service company for the pharmaceutical and lifescience field through the activity of executive managers coming from various business areas where they held important managerial positions at corporate level in various company sectors. Throughout their working experience, these professionals felt the growing need of the sector for reliable, efficient and really skilful service providers. This need arises from the company necessity to focus the internal resources on the core business; in addition, the availability of qualified suppliers allows to create a team integrated with the mandant company personnel, thus providing, in the same time, services and opportunities of professional growth for the involved resources.

OTHER ARTICLES

Comparing HydroxyChloroquine Trials

Article | April 1, 2020

One minor side effect of the pandemic is that perhaps more people will learn about what drug research and clinical trials can really be like. Today’s example: we have a clinical trial of hydroxychloroquine from Wuhan that has just published on a preprint server. What’s good is that this one is blinded, randomized, and controlled (like the earlier hydroxychloroquine which one I blogged about here from Zhejiang University, so we can actually talk about it rather than just spend all our time wondering what the heck is going on.

Read More

Global Antiviral Drugs Market Growth: Is Antiviral Drug the Best Coronavirus Treatment?

Article | April 9, 2020

The global antiviral drugs market has witnessed a rapid surge in demand due to the ongoing Covid-19 pandemic worldwide. So is antiviral drug the best coronavirus treatment? It is still too early to have that conclusion as many medical research and clinical trials are still trying to find the effectiveness and potential side effects of using antiviral drugs to treat coronavirus. But experts believe that antiviral drug might be the best hope for reduce the coronavirus transmission around the world at this stage. However, due to the current difficult situation of the supply chain in many lockdown countries and regions, there is a global shortage on the antiviral drugs supply. With researchers and manufacturers working hard to find and provide effective coronavirus treatment, it is expected that the global antiviral drugs market will have a significant growth over the near future. Antiviral drugs are a type of medication used specifically for treating viral infections, such as human immunodeficiency virus (HIV), hepatitis, and influenza.

Read More

The Future of Pharma Beyond Blockbusters

Article | March 17, 2020

We’ve all heard the saying “treat the patient, not the disease”, and this couldn’t be truer in today’s ever-changing pharmaceutical landscape. We are living in a time of revolution – advancements in genomics and technology are improving our ability to develop precise drugs and targeted therapies, rather than focusing on a one size fits all approach. Each individual’s genetic makeup is slightly different from everyone else’s,

Read More

Top Specialty Pharmacy Therapy Areas

Article | March 16, 2020

Accelerated by advancements in cancer treatments and a growing emphasis on personalized and precision medicine, specialty pharmacy represents a rapidly growing sector within the healthcare industry. In fact, the market is projected to grow to $500 billion by the end of this year—up from $200 billion in total U.S. specialty drug spending in 2017. Industry growth of this magnitude creates challenges for those looking to understand and penetrate the market. It can be difficult, after all, to maintain updated information about high-priority drug therapy areas or facility affiliations in a market that’s constantly changing.

Read More

Spotlight

Pharma D&S

Pharma D&S was born in 2001 as service company for the pharmaceutical and lifescience field through the activity of executive managers coming from various business areas where they held important managerial positions at corporate level in various company sectors. Throughout their working experience, these professionals felt the growing need of the sector for reliable, efficient and really skilful service providers. This need arises from the company necessity to focus the internal resources on the core business; in addition, the availability of qualified suppliers allows to create a team integrated with the mandant company personnel, thus providing, in the same time, services and opportunities of professional growth for the involved resources.

Events